D
Don A. Stevens
Researcher at Norton Healthcare
Publications - 113
Citations - 3895
Don A. Stevens is an academic researcher from Norton Healthcare. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 17, co-authored 71 publications receiving 2768 citations. Previous affiliations of Don A. Stevens include University of Louisville & Washington University in St. Louis.
Papers
More filters
Journal ArticleDOI
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
Jan A. Burger,Alessandra Tedeschi,Paul M. Barr,Tadeusz Robak,Carolyn Owen,Paolo Ghia,Osnat Bairey,Peter Hillmen,Nancy L. Bartlett,Jianyong Li,David Simpson,Sebastian Grosicki,Stephen Devereux,Helen McCarthy,Steven Coutre,Hang Quach,Gianluca Gaidano,Zvenyslava Maslyak,Don A. Stevens,Ann Janssens,Fritz Offner,Jiří Mayer,Michael O'Dwyer,Andrzej Hellmann,Anna Schuh,Tanya Siddiqi,Aaron Polliack,Constantine S. Tam,Deepali Suri,Mei Cheng,Fong Clow,Lori Styles,Danelle F. James,Thomas J. Kipps +33 more
TL;DR: Ibrutinib was superior to chlorambucil in previously untreated patients with CLL or small lymphocytic lymphoma, as assessed by progression-free survival, overall survival, response rate, and improvement in hematologic variables.
Journal ArticleDOI
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial,Brendan M. Weiss,Saad Z. Usmani,Seema Singhal,Ajai Chari,Nizar J. Bahlis,Andrew Belch,Amrita Krishnan,Robert Vescio,Maria-Victoria Mateos,Amitabha Mazumder,Robert Z. Orlowski,Heather J. Sutherland,Joan Bladé,Emma C. Scott,Albert Oriol,Jesus G. Berdeja,Mecide Gharibo,Don A. Stevens,Richard Leblanc,Michael Sebag,Natalie S. Callander,Andrzej Jakubowiak,Darrell White,Javier de la Rubia,Paul G. Richardson,Steen Lisby,Huaibao Feng,Clarissa M. Uhlar,Imran Khan,Tahamtan Ahmadi,Peter M. Voorhees +31 more
TL;DR: Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable safety profile in this population of patients.
Journal ArticleDOI
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei,Andrew H. Wei,Pau Montesinos,Pau Montesinos,VV Ivanov,Courtney D. DiNardo,Jan Novák,Kamel Laribi,Inho Kim,Don A. Stevens,Walter Fiedler,Maria Pagoni,Olga Samoilova,Yu Hu,Achilles Anagnostopoulos,Julie Bergeron,Jing-Zhou Hou,Vidhya Murthy,Takahiro Yamauchi,Andrew McDonald,Brenda Chyla,Sathej Gopalakrishnan,Qi Jiang,Wellington Luiz Mendes,John Hayslip,Panayiotis Panayiotidis +25 more
TL;DR: In this article, patients were randomized 2:1 to venetoclax plus low-dose cytarabine (LDAC) or placebo (n = 68) in 28-day cycles, plus LDAC on days 1 to 10.
Journal ArticleDOI
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Martin Dreyling,Armando Santoro,Luigina Mollica,Sirpa Leppä,George A. Follows,Georg Lenz,Won Seog Kim,Arnon Nagler,Panayiotis Panayiotidis,Judit Demeter,Muhit Ozcan,Marina Kosinova,Krimo Bouabdallah,Franck Morschhauser,Don A. Stevens,David Trevarthen,Marius Giurescu,Lisa Cupit,Li Liu,Karl Köchert,Henrik Seidel,Carol Peña,Shuxin Yin,Florian Hiemeyer,J. Garcia-Vargas,Barrett H. Childs,Pier Luigi Zinzani +26 more
TL;DR: High response rates to copanlisib were associated with high expression of PI3K/B-cell receptor signaling pathway genes, and this phase II study demonstrated significant efficacy and a manageable safety profile in heavily pretreated patients with relapsed or refractory indolent lymphoma.
Journal ArticleDOI
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label phase 3 trial
Sebastian Grosicki,Maryana Simonova,Ivan Spicka,Ludek Pour,Iryrna Kriachok,Maria Gavriatopoulou,Halyna Pylypenko,Holger W. Auner,Xavier Leleu,Vadim A Doronin,Ganna Usenko,Nizar J. Bahlis,Roman Hájek,Reuben Benjamin,Tuphan Kanti Dolai,Dinesh Kumar Sinha,Christopher P. Venner,Mamta Garg,Mercedes Gironella,Artur Jurczyszyn,Pawel Robak,Monica Galli,Craig T. Wallington-Beddoe,Atanas Radinoff,Galina Salogub,Don A. Stevens,Supratik Basu,Anna M. Liberati,Hang Quach,Vesselina Goranova-Marinova,Jelena Bila,Eirini Katodritou,Hanna Oliynyk,Sybiryna Korenkova,Jeevan Kumar,Sundar Jagannath,P. Moreau,Moshe Yair Levy,Darrell White,Moshe E. Gatt,Thierry Facon,Maria V. Mateos,Michele Cavo,Donna E. Reece,Larry D. Anderson,Jean Richard Saint-Martin,Jacqueline Jeha,Anita A. Joshi,Yi Chai,Lingling Li,Vishnuvardhan Peddagali,Melina Arazy,Jatin P. Shah,Sharon Shacham,Michael G. Kauffman,Meletios A. Dimopoulos,Paul G. Richardson,Sosana Delimpasi +57 more
TL;DR: This phase 3, randomised, open-label trial aimed to evaluate the clinical benefit of weekly selinexor, bortezomib, and dexamethasone versus standard bortzomib and dex amethas one in patients with previously treated multiple myeloma.